|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM191C |
Gene summary for TMEM191C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM191C | Gene ID | 645426 |
| Gene name | transmembrane protein 191C | |
| Gene Alias | TMEM191C | |
| Cytomap | 22q11.21 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A6NGB0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 645426 | TMEM191C | LZE7T | Human | Esophagus | ESCC | 6.33e-03 | 1.93e-01 | 0.0667 |
| 645426 | TMEM191C | LZE24T | Human | Esophagus | ESCC | 4.35e-08 | 1.89e-01 | 0.0596 |
| 645426 | TMEM191C | P1T-E | Human | Esophagus | ESCC | 7.11e-04 | 1.82e-01 | 0.0875 |
| 645426 | TMEM191C | P2T-E | Human | Esophagus | ESCC | 5.07e-03 | 4.16e-02 | 0.1177 |
| 645426 | TMEM191C | P4T-E | Human | Esophagus | ESCC | 2.81e-13 | 2.65e-01 | 0.1323 |
| 645426 | TMEM191C | P5T-E | Human | Esophagus | ESCC | 4.72e-09 | 1.66e-01 | 0.1327 |
| 645426 | TMEM191C | P8T-E | Human | Esophagus | ESCC | 1.79e-02 | 5.29e-02 | 0.0889 |
| 645426 | TMEM191C | P9T-E | Human | Esophagus | ESCC | 1.88e-05 | 1.53e-01 | 0.1131 |
| 645426 | TMEM191C | P10T-E | Human | Esophagus | ESCC | 4.41e-07 | 1.54e-01 | 0.116 |
| 645426 | TMEM191C | P11T-E | Human | Esophagus | ESCC | 9.07e-04 | 2.20e-01 | 0.1426 |
| 645426 | TMEM191C | P12T-E | Human | Esophagus | ESCC | 9.20e-17 | 2.85e-01 | 0.1122 |
| 645426 | TMEM191C | P15T-E | Human | Esophagus | ESCC | 5.37e-05 | 1.32e-01 | 0.1149 |
| 645426 | TMEM191C | P16T-E | Human | Esophagus | ESCC | 2.02e-06 | 1.48e-01 | 0.1153 |
| 645426 | TMEM191C | P17T-E | Human | Esophagus | ESCC | 2.60e-06 | 2.36e-01 | 0.1278 |
| 645426 | TMEM191C | P20T-E | Human | Esophagus | ESCC | 4.83e-12 | 3.00e-01 | 0.1124 |
| 645426 | TMEM191C | P21T-E | Human | Esophagus | ESCC | 9.78e-30 | 5.58e-01 | 0.1617 |
| 645426 | TMEM191C | P22T-E | Human | Esophagus | ESCC | 1.39e-09 | 1.63e-01 | 0.1236 |
| 645426 | TMEM191C | P23T-E | Human | Esophagus | ESCC | 7.50e-13 | 3.34e-01 | 0.108 |
| 645426 | TMEM191C | P26T-E | Human | Esophagus | ESCC | 1.03e-15 | 2.45e-01 | 0.1276 |
| 645426 | TMEM191C | P27T-E | Human | Esophagus | ESCC | 2.02e-06 | 1.40e-01 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM191C | SNV | Missense_Mutation | novel | c.941N>A | p.Ser314Tyr | p.S314Y | A6NGB0 | protein_coding | tolerated(0.12) | probably_damaging(0.937) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |